- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novo's Liraglutide Recommended for FDA Approval to Treat Obesity
An FDA advisory committee recommended Thursday that a diabetes drug, liraglutide (Saxenda), be approved for the treatment of obesity.
The Endocrinologic and Metabolic Drugs Advisory Committee voted 14-1 that the benefits of injectable liraglutide, a human GLP-1 analog, outweighed the risks of using the drug.
"This drug seems to have fairly strong evidence of efficacy," said panel member Charles Stanley, MD, of the University of Pennsylvania in Philadelphia. "One of the secondary benefits is risk reduction for diabetes and at least delaying the onset of diabetes, which is very important in these patients."
He added that the company's Risk Evaluation and Mitigation Strategy (REMS) "will be important for monitoring concerns regarding pancreatitis and increased risk of [certain] cancers."
Link to the report on medpage TODAY: http://bit.ly/1oC0Fl0
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
